GlassScriptPhysician profile
Jason R Young
NPI 1205224870
$924.20
in general payments reported to CMS, 2019-2025
17 companies · $605 in 2025
The $605 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $19.21 · 2023: $64.54 · 2024: $236 · 2025: $605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $905.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $904.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $147.65 | 2025 | |
| Amgen INC. | $131.20 | 2024-2025 | Otezla, Repatha, Otezla |
| Lilly USA, LLC | $74.87 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $74.76 | 2022-2025 | |
| Dynavax Technologies Corporation | $66.37 | 2024-2025 | Heplisav-B |
| Phathom Pharmaceuticals, INC. | $62.78 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $54.32 | 2023-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Dexcom, INC. | $52.28 | 2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $48.08 | 2023-2025 | Ozempic, Rybelsus |
| Inspire Medical Systems, INC. | $37.42 | 2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $34.59 | 2025 | Farxiga, Airsupra |
| Pfizer INC. | $31.25 | 2023-2024 | |
| Mylan Specialty L.P. | $30.58 | 2024 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.22 | 2024-2025 | Xifaxan |
| Biogen, INC. | $18.94 | 2025 | Skyclarys |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $17.25 | 2025 | Gemtesa |
| Exact Sciences Corporation | $13.64 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.